Loading data for CTOR — first visit, this takes a few seconds.

アラート

Citius Oncology Inc. (CTOR)

NasdaqCM: CTOR · リアルタイム株価 · USD

0.74

-0.18 (-19.57%)

終値時点： Aug 18, 2026, 8:00 PM

-19.57% (1D)

データがありません

買気配	0.54
時価総額	74.35M
売上高（TTM）	5.61M
純利益（TTM）	-42.51M
ベータ	3.49
EPS（TTM）	-0.44
PER（TTM）	n/a
予想PER	n/a
PBR（TTM）	1.85
PSR（TTM）	13.25
Earnings Date	n/a

売気配	0.98
出来高	274,784
平均出来高（20日）	80,365
始値	0.77
前日終値	0.92
当日レンジ	0.70 - 0.78
52週レンジ	0.49 - 2.25
アナリスト	n/a
目標株価	n/a
配当	n/a
権利落ち日	n/a

CTORについて

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. operates as a subsidiary of Leonard-Meron Biosciences, Inc....

[続きを読む]

業種 Drug Manufacturers - Specialty & Generic

セクター Healthcare

IPO日 Dec 8, 2022

従業員数 n/a

上場取引所 NasdaqCM

ティッカー CTOR

ウェブサイト https://citiusonc.com/overview/default.aspx

企業情報の全文

業績

2025年のCitius Oncologyの売上高は0で、前年の0からundefined%の増加でした。利益は-24.76Mで、17.08%の増加でした。

財務諸表

決算サプライズ

Citius OncologyはAug 14, 2026に四半期決算を発表しました：

売上高は $1.67M で、予想を下回りました $0, うち Infinity% の前年比増加にあたります.

EPSは -0.08 で、予想を下回りました -0.01, うち 0.00% の前年比増加にあたります.

ニュース

1日前 · InvestorsHub

Citius Oncology shares tumble as Q3 revenue misses forecasts despite LYMPHIR launch momentum

Citius Oncology Inc. (NASDAQ:CTOR) shares fell 10.

2か月前 · Insider Monkey

Is Citius Pharmaceuticals, Inc. (CTXR) among the Best Rated Penny Stocks to Buy According to Wall Street Analysts?

With an upside potential of 843.40%, Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) is among the 7 Best Rated Penny Stocks to Buy According to Wall Street Analysts. On May 18, H.C. Wainwright analyst Sway...

3か月前 · Pharmaceutical Technology

Citius raises $36.5m for Lymphir commercialisation

The capital includes a $25m term loan and a warrant exercise agreement expected to yield $11.5m.

4か月前 · Simply Wall St.

Breakeven On The Horizon For Citius Oncology, Inc. (NASDAQ:CTOR)

Citius Oncology, Inc. ( NASDAQ:CTOR ) is possibly approaching a major achievement in its business, so we would like to...

5か月前 · Insider Monkey

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Citius Pharmaceuticals Inc. (NASDAQ:CTXR) is one of the stocks that should double in 3 years. On February 13, Citius Pharmaceuticals officially transitioned into a revenue-generating company following...

2ページ中1ページ

Citius Oncology Inc. (CTOR)